无锡帕母医疗技术有限公司 Mediaroom

Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

SHANGHAI, Aug. 9, 2024 /PRNewswire/ -- Pulnovo Medical Limited,a globally recognized device pioneer...

2024-08-09 17:09 4810

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

SHANGHAI, July 9, 2024 /PRNewswire/ -- Pulnovo Medical, a globally recognized device pioneer in the...

2024-07-09 20:00 1970

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

SHANGHAI, July 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pionee...

2024-07-02 19:10 2270

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pionee...

2024-01-02 20:30 2145

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment

SHANGHAI, March 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platfor...

2023-03-28 20:30 1755

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform...

2023-02-28 10:19 1837

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 14, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform...

2023-01-14 22:00 3801

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 4, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform,...

2023-01-04 10:46 2315

Pulnovo Medical will be attending JPM Healthcare Conference 2023

SHANGHAI, Dec. 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovati...

2022-12-24 20:00 4008

Pulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global Growth

SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM (From Ope...

2022-11-07 20:30 2712

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platfor...

2022-09-23 20:30 2087

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

Pulnovo Medical Announced Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) Meet The Efficacy Primary Endpoint

SHANGHAI, Jan. 1, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pionee...

2022-01-01 20:30 2762

Latest News

Pulnovo Medical Announces First Enrollment in Singapore for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

Pulnovo Medical will be attending JPM Healthcare Conference 2023

Pulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global Growth

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

Pulnovo Medical Released Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH)

Pulnovo Medical Concludes Successfully the First Steering Committee Meeting

Pulnovo Medical Limited's PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH

Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial

Pulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board

SCAI & CBS Pulmonary Hypertension Masterclass 2022: Based on Global Perspectives Focusing on New Breakthroughs

Pulnovo Medical Appoints Ms. Jessie Lian Jia as New CEO

Pulnovo Medical Announced Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) Meet The Efficacy Primary Endpoint